Broad-Spectrum Antibacterial Composition for Drug-Resistant Pathogens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The increasing resistance of bacteria to antibiotics, particularly multidrug-resistant strains, poses a severe threat, with limited development of novel antibiotics due to the scarcity of natural product structures and insufficient investment, necessitating new compounds with broad-spectrum antibacterial activity.
Innovation Solution
Development of a benzoyl aniline derivative, BAB159, with specific substituents, and its combination with polymyxin E, forming a synergistic antibacterial composition effective against a wide range of bacteria and fungi, including multidrug-resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional antibiotics (aminoglycosides, tetracyclines, beta-lactams) are used, then antibacterial activity against specific bacteria is achieved, but broad-spectrum activity is limited and resistance development occurs
Solution Approach 1:
The patent creates a carbapenem compound with a novel substituent structure that simultaneously provides broad-spectrum activity against Gram-positive bacteria, Gram-negative bacteria, and anaerobes. The specific substituent pattern at the R1 position enables the molecule to interact with multiple bacterial targets, achieving universal antibacterial coverage while maintaining high reliability through optimized pharmacodynamic properties.
Solution Approach 2:
The invention combines the carbapenem core structure with specifically designed substituent groups (halogen atoms at R1 position) to create a composite molecular structure. This composite approach integrates the stability of the carbapenem ring system with the enhanced antibacterial properties of the substituted aryl or heteroaryl groups, resulting in a compound that overcomes resistance mechanisms affecting conventional antibiotics.
2Reliability
If existing antibiotics are used, then treatment of common bacterial infections is effective, but treatment of resistant strains including MRSA and VRE fails
Solution Approach 1:
The patent systematically varies substituent parameters at the R1 position of the carbapenem structure, introducing halogen atoms and different aromatic systems to optimize the compound's ability to penetrate resistant bacterial cell walls and bind to penicillin-binding proteins in MRSA and VRE strains. This parameter optimization maintains high antibacterial effectiveness against resistant organisms while preserving activity against susceptible bacteria.
3Stability of the object's composition
If carbapenem compounds with conventional substituents are used, then stability is improved, but antibacterial activity against resistant strains is insufficient
Solution Approach 1:
The invention introduces specific local modifications at the R1 position of the carbapenem molecule, placing halogen substituents and aromatic groups at precise locations to enhance both stability and antibacterial activity. This localized structural optimization allows the molecule to maintain carbapenem stability while gaining enhanced penetration and binding capabilities against resistant bacterial strains, achieving both improved stability and expanded adaptability simultaneously.
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
The present invention relates to a compound with broad-spectrum antibacterial activity and its antibacterial composition. The compound with broad-spectrum antibacterial activity has formula (I). The compound provided by the present invention are novel antibacterial drug source compounds with a broad antibacterial spectrum, good antibacterial activity, suitable in vivo pharmacokinetics, and significant in vivo therapeutic effects. Preferred compound BAB159 has good antibacterial activity against Staphylococcus, Clostridium perfringens, Enterococcus, Bacillus, Streptococcus, Haemophilus, Candida krusei, Aspergillus niger, and Trichophyton, which is comparable or better than the listed drugs. It can enrich molecular library of the antibacterial drug sources, alleviate the severe situation of drug resistance, and provide new treatment options for infections caused by clinically resistant pathogens. The combination of preferred compound BAB159 and polymyxin E exhibits significantly enhanced synergistic antibacterial activity, especially against multidrug-resistant strains.